Source comparison
Clinical Trial Outcomes: Photoprotection vs Adverse Event Rates
The University of Arizona published the largest controlled melanotan-2 comparative study in 2000, enrolling 60 participants with Fitzpatrick skin types I–II (the populations most vulnerable to UV damage). Participants received either 0.16 mg/kg MT-2 or placebo
This comparison does not assign a generated winner or score.
- The University of Arizona published the largest controlled melanotan-2 comparative study in 2000, enrolling 60 participants with Fitzpatrick skin types I–II (the populations most vulnerable to UV damage). Participants received either 0.16 mg/kg MT-2 or placebo over 10 weeks, followed by controlled UV exposure to measure minimal erythemal dose increases. Results showed MED increases of 240% in the MT-2 group versus 12% in placebo after eight weeks of dosing. A photoprotection effect no topical sunscreen can replicate.
- The same trial documented adverse events in 89% of MT-2 participants: nausea (70%), facial flushing (45%), spontaneous erections (40% of males), and decreased appetite (35%). Eight participants discontinued due to intolerable side effects. A 13% dropout rate that pharmaceutical sponsors consider unacceptably high. Post-study surveys found that despite side effects, 72% of completers reported they would use MT-2 again if it were commercially available, citing cosmetic satisfaction with tanning outcomes.
- A 2004 Swedish comparative study took a different approach. Enrolling 32 participants but using a slower dose escalation protocol (starting at 0.025 mg daily, increasing by 0.025 mg every three days). This titration reduced nausea incidence to 35% and erectile dysfunction to 18%, though it extended the time to visible tanning from 10 days to 21 days. The trade-off was clear: slower dosing improves tolerability but delays the cosmetic outcome users seek.
- Post-2010 observational data from unregulated peptide markets tells a darker story. A 2018 Australian survey of 470 self-administering MT-2 users found adverse event rates of 58%, including previously unreported outcomes: mole darkening and growth (12%), hyperpigmented patches (8%), and persistent nausea requiring antiemetic medication (6%). The lack of medical supervision meant dose protocols varied wildly. Some users reported loading doses exceeding 2 mg daily, far above any clinically studied regimen. These findings underscore why melanotan-2 comparative studies conducted in controlled settings may underestimate real-world risk.